In addition, Wang and colleagues (2010) have observed that the use of anastrozole produced higher E2 levels in breast cancer patients treated with aromatase inhibitors, suggesting that the existence of SNPs in aromatase may increase the aromatase activity despite the use of anastrozole [58]. This evidence concerns the gene CYP19A1 and breast cancer.